Let's discuss the problems

This is the problem that we are seeking to address.

We have been informed that the fight against unemployment in the Community is to be given pride of place.

I should like to address a problem which currently hits operators hard in practice.

Secondly, I wish to mention a problem which relates to the protection of personal data.

Thirdly, I raise the problem faced by Scotch whisky.

We must be able to approach the Commission on these issues.

The problem you raise goes a step further.

There is one last point I should like to raise on a major problem of governance.

Finally, I have to address the problem of Parliament in Strasbourg.

The second problem I should like to address concerns administrative matters.

(NL) Mr President, Commissioner, ladies and gentlemen, despite the lateness of the hour there is a problem we would like to broach.

But that is not the problem I want to deal with today.

It can address the problem by getting young people interested in science.

The second point I would like to make is on the issue of governance.

Might I be permitted to raise a very important issue for the British MEPs coming to Strasbourg?

I would like to touch on a problem that you did not mention in your speech, and that is the issue of dividing the treaty into two parts.

The second problem I want to discuss concerns Mr Goerens's report.

Another problem which I wanted to touch upon is the problem of the reception of Albanian victims of trafficking in women.

So if we can address, use technology, help address education, help address the environment, help address the pandemic, does that solve the larger problem that I was talking about in the Wired article? And I'm afraid the answer is really no, because you can't solve a problem with the management of technology with more technology.

There is a second issue I would like to raise.

So if we can address, use technology, help address education, help address the environment, help address the pandemic, does that solve the larger problem that I was talking about in the Wired article?

I would also like to touch upon another problem connected with this, which might perhaps warrant a joint initiative by the Member States.

ACR 20

No single instrument will work everywhere.

At two years, 93.5 (p 0.004) and 86.4 of patients receiving Bondenza 150 mg once monthly or ibandronic acid 2.5 mg daily, respectively, were responders.

At two years, 93.5 (p 0.004) and 86.4 of patients receiving Bonviva 150 mg once monthly or ibandronic acid 2.5 mg daily, respectively, were responders.

I am only able to mention one interesting aspect.

In order to separate the problem of the overall housing deficit from the problem of families with inadequate housing, policymakers need to address both supply and demand.

Response (n qualified for response)

In the course of the conciliation 1 mentioned we should, therefore, in our view, lose no time in starting discussions with a view to defining the conditions of application of Article 203, so as to avoid a repetition of such a crisis in the future, and these discussions should in our opinion extend to the classification into compulsory and noncompulsory expenditure.

I should mention the fundamental problem that key Commission documents are not made available to Parliament and its rapporteurs in good time.

Ten patients achieved a tumour response due to re treatment.

dose for optimal response (once a day or two divided doses)

Percentage of subjects in clinical response and in sustained clinical response Clinical response at Week 8a Clinical response at Week 30a Sustained response (clinical response at both

NA, not available ORR overall response rate CR complete response PR partial response

Well, if we act in that direction I feel that, by the end of the year (and I hope I am wrong but I am afraid on the contrary that 1 shall be right), we shall find ourselves with a larger surplus of butter than the surplus we have this year.

There's one difficulty, sir, a very grave one.

Seven patients in each arm had an objective response.

Of the patients who lost adequate response after re randomization to placebo who then enrolled into the open label extension trial, 38 (25 66) and 55 (36 66) regained PASI 75 response after 12 and 24 weeks of re treatment, respectively.

In an open label extension study, for patients who dose escalated from 40 mg every other week to 40 mg weekly due to a PASI response below 50 and were evaluated at 12 weeks after dose escalation, 59 243 (24.3 ) of patients regained PASI 75 response.

Hypothyroidism may reduce the optimal response to somatropin.

Predictability of response Please refer to section 4.2, in Table 2.

The primary endpoint in Study V was the percent of patients who achieved an ACR 50 response at week 52.

I just want to say a couple quick things.